Expert Outlook: Health Catalyst Through The Eyes Of 7 Analysts
Portfolio Pulse from Benzinga Insights
Health Catalyst (NASDAQ:HCAT) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have set a 12-month price target range of $7.00 to $16.00, with an average target of $12.43, slightly down from $12.71. The company shows positive revenue growth but lags behind industry peers. Despite a negative net margin, ROE, and ROA, Health Catalyst maintains a balanced debt approach.
September 20, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Health Catalyst has received mixed analyst ratings, with a majority being somewhat bullish. The average 12-month price target is $12.43, down from $12.71. The company shows positive revenue growth but lags behind industry peers. Despite a negative net margin, ROE, and ROA, Health Catalyst maintains a balanced debt approach.
The mixed analyst ratings suggest a neutral short-term impact on HCAT's stock price. The slight decrease in the average price target indicates a cautious outlook. However, the company's positive revenue growth and balanced debt management provide some support. The negative net margin, ROE, and ROA are concerns, but the overall sentiment remains somewhat bullish.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100